07 June 2020
Visiongain has launched a new pharma report Digital Pathology Market Report 2020-2030: Forecasts by Product (Device (Scanners, Slide Management System), Software, Storage System), Application (Drug Discovery & Development, Academic Research, Diagnosis (Cancer Cell Detection, Others)), End User (Academic & Research Institutes, Biotech & Pharma Companies, Diagnostic Labs, Hospitals), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).
The global digital pathology market is anticipated to grow at a lucrative CAGR of xyz% and anticipated to reach USD xyz million by 2020. Visiongain anticipates that the global digital pathology market will grow on account of the growing prevalence of chronic diseases coupled with growing healthcare awareness across the globe.
Digital pathology applications provide image analysis with the help of a computer system, high-resolution specimen scanning, and allows pathologists to cross-examine slides with no physical evidence. The growing prevalence of chronic diseases is anticipated to lead to the adoption of digital pathology methods as compared to traditional diagnostic methods since they improve existing inadequate diagnostic imaging interventions for patients and reduces the high cost associated with traditional diagnostics methods.
The global digital pathology market is anticipated to grow on account of growing chronic diseases coupled with a growing aging population across the globe especially in emerging economies of Asia Pacific region. The rise in chronic diseases is attributed to the high mortality rate, according to a study published in Medscape. Moreover, advancement in technology is projected to fuel market growth further over the forecast period.
The growing adoption of computer-aided diagnosis that integrates image processing techniques facilitates the detection of disease more easily. Considering these factors, the digital pathology market is anticipated to witness a lucrative growth rate over the forecast period. However, factors such as unclear reimbursement policies, shortage of skilled professionals, and unwillingness to adopt new technology, are projected to restrain the market growth.
North America dominated the global digital pathology market in the year 2019, owing to the higher adoption of digital pathology systems and is anticipated to continue this trend over the forecast period. The North American digital pathology market is anticipated to grow on account of the easy availability of digital pathology products, the presence of major market players, and growing government investments across the region.
However, the Asia-Pacific digital pathology market is anticipated to grow with the highest CAGR owing to growing demand from emerging economies like India, Japan & China. Also, growing awareness towards the adoption of digital pathology systems, the presence of an enormous patient base suffering from chronic & infectious diseases and an increase in regional healthcare expenditure is projected to boost market growth further. The developing countries like India, China, Japan, & Malaysia are anticipated to offer fresh revenue generation avenues for the global digital pathology companies due to growing demand for medical tourism, rising disposable income, and growing government investments for providing better healthcare facilities to the growing population.
Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global digital pathology market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the digital pathology market.
For instance, on 6th February 2019; Corista, an integrated pathology solutions company, is excited to announce our integration with Visiopharm, a global provider of image analysis software. Corista will extend direct access to Visiopharm’s Oncotopix® from within its award-winning DP3® comprehensive workflow suite. Corista’s DP3 is the digital pathology platform of choice for major medical organizations seeking to create a seamless pathology workflow that integrates with all major digital systems, including all whole slide scanners (WSI) and major laboratory information systems (LIS). The addition of Visiopharm’s quantitative image analytics for analyzing data and images provides pathologists with powerful tools to improve their workflows.
The comprehensive market report features companies such as 3DHISTECH Ltd., APOLLO ENTERPRISE IMAGING, CORISTA, Danaher, Definiens, Digipath, Inc., F. Hoffmann-La Roche Ltd, GLENCOE SOFTWARE, INC, Hamamatsu Photonics, Inc., HURON DIGITAL PATHOLOGY, INDICA LABS, Koninklijke Philips N.V., LEICA BIOSYSTEMS, Mikroscan Technologies, OBJECTIVE PATHOLOGY SERVICES, Olympus Corporation, Omnyx, LLC, OPTRASCAN, INC., SECTRA AB, VISIOPHARM among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Due to increases in the therapies in progress, the dosages provided, & the patient populations targeted, viral vector production capacity has become increasingly reduced in recent years. The condition is aggravated by COVID-19.
03 December 2020
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise over the forecast period. The increase in the drugs abuse creates a huge demand for the drugs of abuse testing products.
03 December 2020
Continuous increasing prevalence of chronic pain is increasing demand for controlled substance as treatment for Chronic pain. Due to which increasing prevalence of chronic pain around the world is working as a driver for the controlled substance market.
03 December 2020
All regions are facing rapid growth in the companion animal population. Companion animal are at high risk of developing various diseases for which companion animal require timely diagnosis for the identification, detection and treatment for life causing diseases.